Sumatriptan-4mg-carton-1s (Sumatriptan 4mg Carton 1s)
Sumatriptan Succinate Injection
Product Images NDC 62332-656
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 22 technical images submitted to the FDA as part of the official labeling for Sumatriptan Succinate (NDC 62332-656). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Alembic Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Sumatriptan-4mg-carton-2s (Sumatriptan 4mg Carton 2s)
This is a description of Sumatriptan Injection in a single-dose autoinjector system. Each prefilled syringe contains 4 mg of Sumatriptan in a 0.5 mL solution for subcutaneous injection. The instructions for use are provided, including steps like pulling off the cap, pressing the button, and observing the needle position before injection. The product should be stored between 2°C and 30°C. The carton contains 2 autoinjectors. The manufacturer is listed as Karahasi with a contact address in Bedminster, NJ, USA.*
Sumatriptan-4mg-pen-label (Sumatriptan 4mg Pen Label)
This description provides details about a single dose autoinjector system containing Sumatriptan for subcutaneous injection. The product includes a pre-filled syringe delivering 5.6 mg of sumatriptan succinate and 3.8 mg of sodium chloride. The autoinjector is sterile and nonpyrogenic and should be stored between 2° and 30°C, protected from light. The manufacturing is done by Alembic Pharmaceuticals, Inc. in India.*
Sumatriptan-4mg (Sumatriptan 4mg)
Sumatriptan-6mg-carton-1s (Sumatriptan 6mg Carton 1s)
Description: This text provides instructions and information for the use of a 6 mg/0.5 mL subcutaneous injection containing sumatriptan. It includes details on how to administer the injection, storage instructions, and manufacturing information. The text also mentions the quantity of medication in the prefilled syringe and the contents of the solution. Additionally, there are details regarding the sterile and non-pyrogenic nature of the injection.*
Sumatriptan-6mg-carton-2s (Sumatriptan 6mg Carton 2s)
This text appears to be a detailed description of a medication called "Sumatriptan Injection, USP" with a concentration of 6 mg/0.5 mL intended for subcutaneous injection only. The medication is packaged in a pre-filled syringe and each syringe contains 5 mL of solution containing 6 mg of sumatriptan succinate, equivalent to 5 g of sumatriptan and 35 mg of sodium chloride. The instructions involve preparing for injection by holding the syringe upright, pressing the plunger down, holding for 5 seconds, and keeping the syringe straight during the injection process. The text also includes information about storage conditions, manufacturer details, and prescribing information.*
Sumatriptan-6mg-pen-label (Sumatriptan 6mg Pen Label)
This text provides information regarding a Single Dose Autoinjector System containing Sumatriptan Injection, USP. Each autoinjector has a prefilled syringe with a solution containing 8.4 mg of sumatriptan succinate equivalent to 6 mg of sumatriptan and 3.5 mg of sodium chloride. It is sterile, nonpyrogenic, and meant for subcutaneous use. The product should be stored between 2° and 30°C (36° and 86°F) and protected from light. This autoinjector is manufactured by Alembic Pharmaceuticals, Inc., based in Bedminster, NJ 07921, USA, and made in India.*
Sumatriptan-6mg (Sumatriptan 6mg)
Sumatriptan-features2 (Sumatriptan Features2)
This text appears to contain instructions related to using pre-filled auto-injectors for injections. It mentions actions like removing the cap before injection and post-injection steps. The text emphasizes the preparation and use of pre-filled auto-injectors for medical purposes.*
Sumatriptan-figure-1 (Sumatriptan Figure 1)
This information presents the estimated percentage of patients experiencing relief with placebo (127 patients) and sumatriptan (131 patients) over time. The graph shows that after 20 minutes, about 100% of patients experienced relief with both placebo and sumatriptan, with a gradual increase starting from 10 minutes and reaching maximum relief at 20 minutes.*
Sumatriptan-ifu-fig-a (Sumatriptan Ifu Fig A)
Sumatriptan-ifu-fig-b (Sumatriptan Ifu Fig B)
Sumatriptan-ifu-fig-c (Sumatriptan Ifu Fig C)
Sumatriptan-ifu-fig-d (Sumatriptan Ifu Fig D)
Sumatriptan-ifu-fig-e (Sumatriptan Ifu Fig E)
Sumatriptan-ifu-fig-f (Sumatriptan Ifu Fig F)
Sumatriptan-ifu-fig-g (Sumatriptan Ifu Fig G)
Sumatriptan-ifu-fig-h (Sumatriptan Ifu Fig H)
Sumatriptan-ifu-fig-i (Sumatriptan Ifu Fig I)
Sumatriptan-ifu-fig-j. (Sumatriptan Ifu Fig J)
Sumatriptan-ifu-fig-k (Sumatriptan Ifu Fig K)
Sumatriptan-structure (Sumatriptan Structure)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
